Allergan, Inc. Announces FDA Approval Of JUVEDERM(R) XC Dermal Filler Formulated With Lidocaine

3 Feb
2010

Allergan, Inc. (NYSE:AGN) announced the U.S. Food and Drug Administration’s (FDA) approval of JUVEDERM(R) XC, a new formulation of the currently FDA-approved JUVEDERM(R) dermal filler and the latest advancement1 in hyaluronic acid (HA) dermal fillers.

Continued here:
Allergan, Inc. Announces FDA Approval Of JUVEDERM(R) XC Dermal Filler Formulated With Lidocaine

Comment Form

Copryright 2012 - Epione Medical Corporation | About us | Treatments | Contact us | Online Store

Share to Facebook Share to Twitter Stumble It Email This More...